FINWIRES · TerminalLIVE
FINWIRES

Japan Stocks Close Lower After Nikkei Briefly Tops 60,000

-- Japanese equities closed in negative territory on Monday, reversing early gains after the benchmark briefly crossed the 60,000 level, as profit-taking set in following a tech-led rally and easing geopolitical risk tied to the extended Iran-U.S. ceasefire.

The Nikkei 225 ended 0.75% lower, or fell 445.63 points, to close at 59,140.23.

The decline came as investors reassessed geopolitical risks and tracked softer U.S. futures, despite no further escalation in the Middle East.

The Nikkei 225 briefly hit a record 60,013.98, with early gains supported by an extended Iran-U.S. ceasefire. While the ceasefire was prolonged following mediation efforts, tensions persisted as a U.S. naval blockade remained in place and Iran seized two vessels in the Strait of Hormuz.

In economic news, Japan's private sector growth slowed to a four-month low in April as a surge in manufacturing-driven by supply concerns-was offset by softer services activity, with the S&P Global Flash Japan PMI Composite Output Index easing to 52.4 from 53.

Rising input costs linked to energy and a weak yen pushed prices higher, while business confidence fell to its lowest level since August 2020 amid Middle East uncertainty.

On the corporate front, Japan Petroleum Exploration (TYO:1662) rose 9% after outlining plans to boost oil and gas output to 180,000 bpd by 2035 with a 1.16 trillion yen investment, shifting focus toward energy security.

Toyota Motor (TYO:7203) fell 2% after a report said it is reviewing a potential data breach involving seconded staff from insurers under Tokio Marine (TYO:8766) and MS&AD Insurance Group (TYO:8725).

Note (TYO:5243) dropped 8% after its founder sold 2.8% of outstanding shares in a move aimed at improving stock liquidity.

相关文章

Australia

再生元公司称,FDA已加速批准其治疗遗传性听力损失的疗法

再生元公司(Regeneron,股票代码:REGN)周四宣布,美国食品药品监督管理局(FDA)已加速批准其治疗OTOF基因相关听力损失的药物Otarmeni用于治疗儿童和成人患者。 根据一份声明,FDA的批准基于正在进行的Chord试验。该试验显示,20名受试者中有16名在纯音测听评估中听力有所改善,其中14名表现出听觉脑干反应。 再生元公司表示,Otarmeni的持续批准可能取决于Chord试验验证性部分中临床获益的验证和描述。 该公司表示,将为美国符合临床条件的患者免费提供Otarmeni。 该公司股价周四上涨2%。Price: $761.47, Change: $+14.89, Percent Change: +1.99%

$REGN
Sectors

行业动态:医疗保健

周四下午,医疗保健类股下跌,纽约证券交易所医疗保健指数下跌0.5%,道富医疗保健精选行业SPDR ETF (XLV)下跌0.7%。 iShares生物技术ETF (IBB)下跌1.9%。 公司新闻方面,赛默飞世尔科技(TMO)周四上调了全年业绩预期,原因是其第一季度业绩强于预期,尽管内生增长低于分析师预期。该公司股价下跌10.9%。

$TMO
Research

美国银行称,德州仪器将受益于工业复苏和数据中心需求增长。

美国银行周四发布的一份报告指出,德州仪器 (TXN) 有望受益于工业复苏,尤其是在航空航天/国防、数据中心需求以及其美国本土制造业务带来的收益增长。 该券商还表示,随着德州仪器逐步摆脱大规模资本支出周期,其自由现金流有望更加强劲。报告还指出,德州仪器能够利用过去三年在美国晶圆厂的巨额资本支出,在“资源受限”的芯片市场中抢占市场份额。 美国银行还表示,看好德州仪器在直流电源领域的定位,该公司“在机架级产品中占据主导地位,并且随着架构向更高电压/更高功率密度系统发展,其专用插座业务也呈现增长势头”。 然而,美国银行指出,持续的地缘政治动荡仍然是整个行业面临的风险,但补充说,德州仪器历来具有相对更强的防御性。 美国银行将该股评级从“中性”上调至“买入”,并将目标价从 235 美元上调至 320 美元。Price: $283.62, Change: $+47.31, Percent Change: +20.02%

$TXN